• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

研究抗高血压药物抗动脉粥样硬化作用的试验。

Trials investigating the anti-atherosclerotic effects of antihypertensive drugs.

作者信息

Zanchetti A

机构信息

Istituto di Clinica Medica e Terapia Medica, Università di Milano, Italy.

出版信息

J Hypertens Suppl. 1996 Sep;14(2):S77-80; discussion S80-1. doi: 10.1097/00004872-199609002-00015.

DOI:10.1097/00004872-199609002-00015
PMID:8934382
Abstract

METHODS OF CURRENT TRIALS

Several ongoing trials are investigating the anti-atherosclerotic effects of antihypertensive drugs in hypertensive patients. Changes in carotid intimal-medial thicknesses and atherosclerotic plaques are being explored by a sensitive quantitative B-mode ultrasound technique. MULTICENTER ISRADIPINE/DIURETIC ATHEROSCLEROSIS STUDY (MIDAS): The results from this pioneering study indicated a slower progression, at least in the first 6 months, of carotid plaques in isradipine-treated patients than in diuretic-treated patients. MIDAS has been particularly valuable in giving information on the rate of growth of intimal-medial thickness in hypertensive patients and on the best end-point to use in carotid ultrasound trials. EUROPEAN LACIDIPINE STUDY ON ATHEROSCLEROSIS (ELSA) AND VERAPAMIL IN HYPERTENSION AND ATHEROSCLEROSIS STUDY (VHAS): Baseline data from these two ongoing studies have provided evidence of the very high prevalence of carotid lesions among hypertensive patients: the prevalence of plaques (defined as a carotid intimal-medial thickness of > or = 1.3 mm) was 83% in ELSA, while in VHAS, in which plaques were defined as an intimal-medial thickness of > 1.5 mm), the plaque prevalence was 37%. These observations emphasize the importance of evaluating the atherosclerotic action of antihypertensive agents. PLAQUE HYPERTENSION LIPID-LOWERING ITALIAN STUDY (PHYLLIS): This trial is using a factorial design to explore the anti-atherosclerotic action of an angiotensin converting enzyme (ACE) inhibitor (fosinopril) versus a diuretic, and also intends to evaluate the possible benefits of associating antihypertensive therapy with a statin to induce lipid-lowering to prevent the progression of carotid atherosclerosis.

摘要

当前试验方法

多项正在进行的试验正在研究抗高血压药物对高血压患者的抗动脉粥样硬化作用。一种灵敏的定量B型超声技术正在探索颈动脉内膜中层厚度和动脉粥样硬化斑块的变化。多中心伊拉地平/利尿剂动脉粥样硬化研究(MIDAS):这项开创性研究的结果表明,至少在最初6个月内,接受伊拉地平治疗的患者颈动脉斑块进展比接受利尿剂治疗的患者慢。MIDAS在提供高血压患者内膜中层厚度生长速率以及颈动脉超声试验中最佳终点信息方面特别有价值。欧洲拉西地平动脉粥样硬化研究(ELSA)和维拉帕米高血压与动脉粥样硬化研究(VHAS):这两项正在进行的研究的基线数据提供了证据,证明高血压患者中颈动脉病变的患病率非常高:在ELSA中,斑块(定义为颈动脉内膜中层厚度≥1.3毫米)的患病率为83%,而在VHAS中,斑块定义为内膜中层厚度>1.5毫米,斑块患病率为37%。这些观察结果强调了评估抗高血压药物动脉粥样硬化作用的重要性。斑块高血压降脂意大利研究(PHYLLIS):该试验采用析因设计来探索血管紧张素转换酶(ACE)抑制剂(福辛普利)与利尿剂的抗动脉粥样硬化作用,还打算评估将抗高血压治疗与他汀类药物联合使用以诱导降脂预防颈动脉粥样硬化进展的可能益处。

相似文献

1
Trials investigating the anti-atherosclerotic effects of antihypertensive drugs.研究抗高血压药物抗动脉粥样硬化作用的试验。
J Hypertens Suppl. 1996 Sep;14(2):S77-80; discussion S80-1. doi: 10.1097/00004872-199609002-00015.
2
Antiatherosclerotic effects of antihypertensive drugs: recent evidence and ongoing trials.抗高血压药物的抗动脉粥样硬化作用:最新证据与正在进行的试验
Clin Exp Hypertens. 1996 Apr-May;18(3-4):489-99. doi: 10.3109/10641969609088979.
3
The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness.维拉帕米治疗高血压和动脉粥样硬化研究(VHAS):维拉帕米或氯噻酮长期随机治疗对颈动脉内膜中层厚度的影响结果
J Hypertens. 1998 Nov;16(11):1667-76. doi: 10.1097/00004872-199816110-00014.
4
MIDAS: hypertension and atherosclerosis. A trial of the effects of antihypertensive drug treatment on atherosclerosis. MIDAS Research Group.
J Cardiovasc Pharmacol. 1992;19 Suppl 3:S16-20.
5
The hypertensive patient with multiple risk factors: is treatment really so difficult?患有多种危险因素的高血压患者:治疗真的如此困难吗?
Am J Hypertens. 1997 Oct;10(10 Pt 2):223S-229S. doi: 10.1016/s0895-7061(97)00327-0.
6
Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS--a randomized double-blind trial.基于福辛普利或氢氯噻嗪的降压方案联合或不联合普伐他汀降脂对无症状性颈动脉粥样硬化进展的不同影响:PHYLLIS随机双盲试验的主要结果
Stroke. 2004 Dec;35(12):2807-12. doi: 10.1161/01.STR.0000147041.00840.59. Epub 2004 Oct 28.
7
Multicenter isradipine diuretic atherosclerosis study (MIDAS). Design features. The Midas Research Group.多中心伊拉地平利尿剂动脉粥样硬化研究(MIDAS)。设计特点。MIDAS研究小组。
Am J Med. 1989 Apr 17;86(4A):37-9. doi: 10.1016/0002-9343(89)90188-5.
8
Evaluating the benefits of an antihypertensive agent using trials based on event and organ damage: the Systolic Hypertension in the Elderly Long-term Lacidipine (SHELL) trial and the European Lacidipine Study on Atherosclerosis (ELSA).利用基于事件和器官损伤的试验评估抗高血压药物的益处:老年收缩期高血压长期拉西地平(SHELL)试验和欧洲拉西地平动脉粥样硬化研究(ELSA)。
J Hypertens Suppl. 1995 Dec;13(4):S35-9. doi: 10.1097/00004872-199512002-00006.
9
MIDAS: rationale, design and descriptive data of trial patients. The MIDAS Research Group.
Blood Press Suppl. 1994;1:29-35.
10
Calcium antagonists and atherosclerosis protection in hypertension.钙拮抗剂与高血压患者的动脉粥样硬化保护
Am J Ther. 2003 Nov-Dec;10(6):409-14. doi: 10.1097/00045391-200311000-00006.

引用本文的文献

1
Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study.坎地沙坦酯对高血压糖尿病患者颈动脉重构的影响:MITEC研究
Vasc Health Risk Manag. 2009;5(1):175-83. doi: 10.2147/vhrm.s3409. Epub 2009 Apr 8.